Aurinia Pharmaceuticals Inc. Comprehensive Income
Aurinia Pharmaceuticals Inc. (AUPH) reported Comprehensive Income of $37.32 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was $37.32M, a 74.11% increase year-over-year.
- Aurinia Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was $34.07M, a 47.09% increase year-over-year.
- Aurinia Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $210.94M, a 17975.75% increase year-over-year.
- Aurinia Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was $31.71M, a 113.89% increase year-over-year.
- Aurinia Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was $287.25M, a 4822.88% increase from fiscal 2024.
- Aurinia Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was $5.83M.
- Aurinia Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$77.69M.
- Aurinia Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$108.39M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $37.32M 10-Q · filed 2026-08-06 | $71.39M 10-Q · filed 2026-08-06 | $282.33M derived: sum of 3 quarters · filed 2026-08-06 | $314.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $34.07M 10-Q · filed 2026-05-07 | $245.02M derived: sum of 2 quarters · filed 2026-05-07 | $276.73M derived: sum of 3 quarters · filed 2026-05-07 | $298.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $210.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $242.65M derived: sum of 2 quarters · filed 2026-02-26 | $264.08M derived: sum of 3 quarters · filed 2026-08-06 | $287.25M 10-K · filed 2026-02-26 |
| 2025-09-30 | $31.71M 10-Q · filed 2025-11-04 | $53.14M derived: sum of 2 quarters · filed 2026-08-06 | $76.31M 10-Q · filed 2025-11-04 | $77.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $21.43M 10-Q · filed 2026-08-06 | $44.60M 10-Q · filed 2026-08-06 | $45.77M derived: sum of 3 quarters · filed 2026-08-06 | $60.59M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $23.17M 10-Q · filed 2026-05-07 | $24.33M derived: sum of 2 quarters · filed 2026-05-07 | $39.16M derived: sum of 3 quarters · filed 2026-05-07 | $39.87M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $15.99M derived: sum of 2 quarters · filed 2026-02-26 | $16.71M derived: sum of 3 quarters · filed 2026-02-26 | $5.83M 10-K · filed 2026-02-26 |
| 2024-09-30 | $14.82M 10-Q · filed 2025-11-04 | $15.54M derived: sum of 2 quarters · filed 2025-11-04 | $4.67M 10-Q · filed 2025-11-04 | -$21.99M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $717.00K 10-Q · filed 2025-07-31 | -$10.16M 10-Q · filed 2025-07-31 | -$36.81M derived: sum of 3 quarters · filed 2026-02-26 | -$50.19M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$10.87M 10-Q · filed 2025-05-12 | -$37.53M derived: sum of 2 quarters · filed 2026-02-26 | -$50.91M derived: sum of 3 quarters · filed 2026-02-26 | -$62.43M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$26.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$40.03M derived: sum of 2 quarters · filed 2026-02-26 | -$51.56M derived: sum of 3 quarters · filed 2026-02-26 | -$77.69M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$13.37M 10-Q · filed 2024-11-07 | -$24.90M derived: sum of 2 quarters · filed 2024-11-07 | -$51.03M 10-Q · filed 2024-11-07 | -$76.61M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$11.52M 10-Q · filed 2024-08-01 | -$37.66M 10-Q · filed 2024-08-01 | -$63.24M derived: sum of 3 quarters · filed 2025-02-27 | -$71.90M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$26.13M 10-Q · filed 2024-05-02 | -$51.71M derived: sum of 2 quarters · filed 2025-02-27 | -$60.38M derived: sum of 3 quarters · filed 2025-02-27 | -$96.13M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$25.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$34.24M derived: sum of 2 quarters · filed 2025-02-27 | -$69.99M derived: sum of 3 quarters · filed 2025-02-27 | -$108.39M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$8.66M 10-Q · filed 2023-11-02 | -$44.41M derived: sum of 2 quarters · filed 2023-11-02 | -$82.81M 10-Q · filed 2023-11-02 | -$116.19M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | -$35.75M 10-Q · filed 2023-08-03 | -$74.15M 10-Q · filed 2023-08-03 | -$107.53M derived: sum of 3 quarters · filed 2024-02-15 | -$157.78M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$38.40M 10-Q · filed 2023-05-04 | -$71.78M derived: sum of 2 quarters · filed 2024-02-15 | -$122.03M derived: sum of 3 quarters · filed 2024-02-15 | -$169.04M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$33.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$83.64M derived: sum of 2 quarters · filed 2024-02-15 | -$130.64M derived: sum of 3 quarters · filed 2024-02-15 | -$181.01M 10-K · filed 2024-02-15 |
| 2021-09-30 | -$50.26M 10-Q · filed 2022-11-03 | -$97.26M derived: sum of 2 quarters · filed 2022-11-03 | -$147.63M 10-Q · filed 2022-11-03 | -$155.71M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$47.00M 10-Q · filed 2022-08-04 | -$97.38M 10-Q · filed 2022-08-04 | -$105.45M derived: sum of 3 quarters · filed 2023-02-28 | -$147.58M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$50.37M 10-Q · filed 2022-05-10 | -$58.45M derived: sum of 2 quarters · filed 2023-02-28 | -$100.58M derived: sum of 3 quarters · filed 2023-02-28 | -$127.12M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$8.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$50.20M derived: sum of 2 quarters · filed 2023-02-28 | -$76.75M derived: sum of 3 quarters · filed 2023-02-28 | -$102.68M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$42.13M 10-Q · filed 2021-11-03 | -$68.67M derived: sum of 2 quarters · filed 2021-11-03 | -$94.61M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | -$26.54M 10-Q · filed 2021-08-05 | -$52.48M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | -$25.93M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | -$88.39M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |